Medullary thyroid carcinoma: surgical treatment advances

References

• Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab.91(1), 313–319 (2006).
   PubMed Web of Science ®Google Scholar
• Casella C, Fusco M. Thyroid cancer. Epidemiol. Prev.28(2 Suppl.), 88–91 (2004).
   PubMedGoogle Scholar
• Wong KT, Ahuja AT. Ultrasound of thyroid cancer. Cancer Imaging5, 157–166 (2005).
   PubMedGoogle Scholar
• Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid15(7), 708–717 (2005).
   PubMedGoogle Scholar
• Rosai J. Handling of thyroid follicular patterned lesions. Endocr. Pathol.16, 279–283 (2005).
   PubMed Web of Science ®Google Scholar
• LiVolsi VA. Well differentiated thyroid carcinoma. Clin. Oncol. (R. Coll. Radiol.)8, 281–288 (1996).
   Google Scholar
• Clayman GL, el-Baradie TS. Medullary thyroid cancer. Otolaryngol. Clin. N. Am.36(1), 91–105 (2003).
   PubMed Web of Science ®Google Scholar
• You YN, Lakhani V, Wells SA Jr, Moley JF. Medullary thyroid cancer. Surg. Oncol. Clin. N. Am.15(3), 639–660 (2006).
   PubMed Web of Science ®Google Scholar
• Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity.J. Clin. Endocrinol. Metab.19(1), 152–161 (1959).
   PubMed Web of Science ®Google Scholar
• Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer79(1), 132–138 (1997).
   PubMed Web of Science ®Google Scholar
• Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer77(8), 1556–1565 (1996).
   Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer83(12), 2638–2648 (1998).
   PubMed Web of Science ®Google Scholar
• Al-Rawi M, Wheeler MH. Medullary thyroid carcinoma – update and present management controversies. Ann. R. Coll. Surg. Engl.88(5), 433–438 (2006).
   PubMed Web of Science ®Google Scholar
• Dunn JM, Farndon JR. Medullary thyroid carcinoma. Br. J. Surg.80(1), 6–9 (1993).
   PubMed Web of Science ®Google Scholar
• Takami H. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocr. Pathol.14(2), 123–131 (2003).
   Google Scholar
• Wolfe HJ, Melvin KE, Cervi-Skinner SJ et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N. Engl. J. Med.289(9), 437–441 (1973).
   PubMed Web of Science ®Google Scholar
• Machens A, Niccoli-Sire P, Hoegel J et al.; European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med.349(16), 1517–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Machens A, Holzhausen HJ, Thanh PN, Dralle H. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery134(3), 425–431 (2003).
   Google Scholar
• Beressi N, Campos JM, Beressi JP et al. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid8(11), 1039–1044 (1998).
   Google Scholar
• Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann. Surg.229(6), 880–887 (1999).
   PubMed Web of Science ®Google Scholar
• Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer88(5), 1139–1148 (2000).
   PubMed Web of Science ®Google Scholar
• Dolan SJ, Russell CF. Medullary thyroid carcinoma in Northern Ireland, 1967–1997. Ann. R. Coll. Surg. Engl.82(3), 156–161 (2000).
   Google Scholar
• Russo D, Arturi F, Chiefari E et al. A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto-oncogene somatic mutation in fine-needle aspirate specimens. J. Clin. Endocrinol. Metab.82(10), 3378–3382 (1997).
   Google Scholar
• Takano T, Miyauchi A, Matsuzuka F et al. Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy. J. Clin. Endocrinol. Metab.84(3), 951–955 (1999).
   PubMed Web of Science ®Google Scholar
• Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J. Clin. Endocrinol. Metab.89(1), 163–168 (2004).
   PubMed Web of Science ®Google Scholar
• Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses. Thyroid10(10), 919–922 (2000).
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Donis-Keller H. Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes. Endocrinol. Metab. Clin. N. Am.23(1), 215–228 (1994).
   Google Scholar
• Hyer SL, Vini L, A’Hern R, Harmer C. Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur. J. Surg. Oncol.26(7), 686–690 (2000).
   PubMed Web of Science ®Google Scholar
• Weber T, Schilling T, Frank-Raue K et al. Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery.130(6), 1044–1049 (2001).
   PubMed Web of Science ®Google Scholar
• Franc S, Niccoli-Sire P, Cohen R et al. French Medullary Study Group (GETC). Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.)55(3), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Rougier P, Parmentier C, Laplanche A et al. Medullary thyroid carcinoma: prognostic factors and treatment. Int. J. Radiat. Oncol. Biol. Phys.9(2), 161–169 (1983).
   Google Scholar
• Sarrazin D, Fontaine F, Rougier P et al. Role of radiotherapy in the treatment of medullary cancer of the Thyroid Bull. Cancer71(3), 200–208 (1984).
   Google Scholar
• Phay JE, Moley JF, Lairmore TC. Multiple endocrine neoplasias. Semin. Surg. Oncol.18(4), 324–332 (2000).
   Google Scholar
• Melvin KE, Tashjian AH Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog. Horm. Res.28, 399–470 (1972).
   PubMedGoogle Scholar
• Gagel RF, Tashjian AH Jr, Cummings T et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience. N. Engl. J. Med.318(8), 478–484 (1988).
   PubMedGoogle Scholar
• Brandi ML, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab.86(12), 5658–5671 (2001).
   PubMed Web of Science ®Google Scholar
• Carney JA, Sizemore GW, Hayles AB. Multiple endocrine neoplasia, type 2B. Pathobiol. Annu.8, 105–153 (1978).
   PubMedGoogle Scholar
• Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J. Pediatr. Surg.31(1), 177–181 (1996).
   Google Scholar
• Sanso GE, Domene HM, Garcia R et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer94(2), 323–330 (2000).
   Google Scholar
• Eng C. RET proto-oncogene in the development of human cancer. J. Clin. Oncol.17(1), 380–393 (1999).
   PubMed Web of Science ®Google Scholar
• Frilling A, Dralle H, Eng C, Raue F, Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery118(6), 1099–1103 (1995).
   PubMedGoogle Scholar
• Wohllk N, Cote GJ, Evans DB, Goepfert H, Ordonez NG, Gagel RF. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol. Metab. Clin. N. Am.25(1), 1–25 (1996).
   PubMedGoogle Scholar
• Ball DW. Medullary thyroid cancer: therapeutic targets and molecular markers. Curr. Opin. Oncol.19(1), 18–23 (2007).
   PubMed Web of Science ®Google Scholar
• Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, Hoppner W. A RET double mutation in the germline of a kindred with FMTC. Exp. Clin. Endocrinol. Diabetes108(2), 128–132 (2000).
   PubMed Web of Science ®Google Scholar
• Siggelkow H, Melzer A, Nolte W, Karsten K, Hoppner W, Hufner M. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. Eur. J. Endocrinol.144(5), 467–473 (2001).
   Google Scholar
• Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H. Genotype–phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J. Clin. Endocrinol. Metab.86(3), 1104–1109 (2001).
   PubMed Web of Science ®Google Scholar
• Gimm O, Niederle BE, Weber T et al. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome? Surgery132(6), 952–959 (2002).
   Google Scholar
• Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann. Surg.236(5), 570–575 (2002).
   Google Scholar
• Carlson KM, Bracamontes J, Jackson CE et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am. J. Hum. Genet.55(6), 1076–1082 (1994).
   PubMedGoogle Scholar
• Fleming JB, Lee JE, Bouvet M et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann. Surg.230(5), 697–707 (1999).
   PubMed Web of Science ®Google Scholar
• Dralle H, Scheumann GF, Proye C et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Intern. Med.238(4), 357–361 (1995).
   PubMedGoogle Scholar
• Keatts EL, Itano J. Medullary thyroid cancer and the impact of genetic testing. Clin. J. Oncol. Nurs.10(5), 571–575 (2006).
   PubMedGoogle Scholar
• Shaha AR, Cohen T, Ghossein R, Tuttle RM. Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members. Laryngoscope116(9), 1704–1707 (2006).
   PubMed Web of Science ®Google Scholar
• Tashjian AH Jr, Melvin EW. Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N. Engl. J. Med.279(6), 279–283 (1968).
   PubMed Web of Science ®Google Scholar
• Melvin KE, Tashjian AH Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog. Horm. Res.28, 399–470 (1972).
   PubMedGoogle Scholar
• Jackson CE, Tashjian AH Jr, Block MA. Detection of medullary thyroid cancer by calcitonin assay in families. Ann. Intern. Med.78(6), 845–852 (1973).
   PubMed Web of Science ®Google Scholar
• Niccoli-Sire P, Murat A, Baudin E et al. Early or prophylactic thyroidectomy in MEN2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumors Study Group (GETC). Eur. J. Endocrinol.141(5), 468–474 (1999).
   Google Scholar
• Niccoli-Sire P, Murat A, Rohmer V, French Calcitonin Tumors Group (GETC). Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype–genotype relationship in a large series of patients. J. Clin. Endocrinol. Metab.86(8), 3746–3753 (2001).
   Google Scholar
• Vitale G, Ciccarelli A, Caraglia M et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin. Chem.48(9), 1505–1510 (2002).
   Google Scholar
• Cohen R, Campos JM, Salaun C. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etudes des Tumeurs a Calcitonine (GETC). J. Clin. Endocrinol. Metab.85(2), 919–922 (2000).
   PubMed Web of Science ®Google Scholar
• Pomares FJ, Rodriguez JM, Nicolas F et al. Presurgical assessment of the tumor burden of familial medullary thyroid carcinoma by calcitonin testing. J. Am. Coll. Surg.195(5), 630–634 (2002).
   Google Scholar
• Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’Etude des Tumeurs a Calcitonine. Clin. Endocrinol. (Oxf.)48(3), 265–273 (1998).
   PubMed Web of Science ®Google Scholar
• Bachelot A, Lombardo F, Baudin E, Bidart JM, Schlumberger M. Inheritable forms of medullary thyroid carcinoma. Biochimie84(1), 61–66 (2002).
   Google Scholar
• Fugazzola L, Cerutti N, Mannavola D et al. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin. Endocrinol. (Oxf.)56(1), 53–63 (2002).
   Google Scholar
• O’Riordain DS, O’Brien T, Weaver AL et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery116(6), 1017–1023 (1994).
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Travagli JP, Caillou B et al. Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course. Cancer94(1), 44–50 (2002).
   PubMedGoogle Scholar
• Shan L, Nakamura M, Nakamura Y et al. Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Jpn. J. Cancer Res.89(9), 883–836 (1998).
   PubMedGoogle Scholar
• Gagner M, Lacroix A, Prinz RA. Early experience with laparoscopic approach for adrenalectomy. Surgery114(6), 1120–1124 (1993).
   PubMedGoogle Scholar
• Duh QY. Minimally invasive endocrine surgery: standard of treatment or hype? Surgery134(6), 849–857 (2003).
   PubMed Web of Science ®Google Scholar
• Gagner M. Endoscopic parathyroidectomy. Br. J. Surg.83, 87 (1996).
   PubMedGoogle Scholar
• Ohgami M, Ishii S, Ohmori T, Noga K, Furukawa T, Kitajima M. Scarless endoscopic thyroidectomy: breast approach better cosmesis.Surg. Laparosc. Endosc. Percutan. Tech.10, 1–4 (2000).
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Takami H, Sasaki Y, Takayama J, Niimi M, Kan S. Clinical benefits in endoscopic thyroidectomy by the axillary approach. J. Am. Coll. Surg.196(2), 189–195 (2003).
   PubMed Web of Science ®Google Scholar
• Miccoli P, Berti P, Materazzi G, Minuto M, Barellini L. Minimally invasive video-assisted thyroidectomy: five years of experience. J. Am. Coll. Surg.199(2), 243–248 (2004).
   PubMed Web of Science ®Google Scholar
• Miccoli P, Bellantone R, Mourad M, Walz M, Raffaelli M, Berti P. Minimally invasive video-assisted thyroidectomy: multiinstitutional experience.World J. Surg.26(8), 972–975 (2002).
   PubMed Web of Science ®Google Scholar
• Berti P, Materazzi G, Picone A, Miccoli P. Limits and drawbacks of video-assisted parathyroidectomy. Br. J. Surg.90, 743–747 (2003).
   PubMedGoogle Scholar
• Spinelli C, Bertocchini A, Antonelli A, Miccoli P. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. J. Pediatr. Surg.39(10), 1500–1505 (2004).
   PubMed Web of Science ®Google Scholar
• Miccoli P, Elisei R, Berti P et al. Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers. J. Endocrinol. Invest.27(6), 557–561 (2004).
   PubMed Web of Science ®Google Scholar
• Miccoli P, Elisei R, Donatini G, Materazzi G, Berti P. Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience. Surg. Endosc.21(1), 120–123 (2007).
   PubMed Web of Science ®Google Scholar
• Hodges FM, Svoboda JS, Van Howe RS. Prophylactic interventions on children: balancing human rights with public health. J. Med. Ethics28(1), 10–16 (2002).
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol.21(12), 2397–2406 (2003).
   PubMed Web of Science ®Google Scholar
• Anderlik MR, Lisko EA. Medicolegal and ethical issues in genetic cancer syndromes. Semin. Surg. Oncol.18(4), 339–346 (2000).
   Google Scholar
• Harris M, Winship I, Spriggs M. Controversies and ethical issues in cancer-genetics clinics. Lancet Oncol.6(5), 301–310 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer T, Hamelmann W, Timmermann W, Meyer B, Hocht B. The advantages and disadvantages of nerve monitoring during thyroid surgery in childhood. Eur. J. Pediatr. Surg.16(6), 392–295 (2006).
   Google Scholar